190 related articles for article (PubMed ID: 37052770)
1. Rapamycin restores peripheral blood flow in aged mice and in mouse models of atherosclerosis and Alzheimer's disease.
Van Skike CE; DeRosa N; Galvan V; Hussong SA
Geroscience; 2023 Jun; 45(3):1987-1996. PubMed ID: 37052770
[TBL] [Abstract][Full Text] [Related]
2. mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease.
Van Skike CE; Hussong SA; Hernandez SF; Banh AQ; DeRosa N; Galvan V
J Neurosci; 2021 May; 41(19):4305-4320. PubMed ID: 33888602
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.
Van Skike CE; Jahrling JB; Olson AB; Sayre NL; Hussong SA; Ungvari Z; Lechleiter JD; Galvan V
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H693-H703. PubMed ID: 29351469
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.
Spilman P; Podlutskaya N; Hart MJ; Debnath J; Gorostiza O; Bredesen D; Richardson A; Strong R; Galvan V
PLoS One; 2010 Apr; 5(4):e9979. PubMed ID: 20376313
[TBL] [Abstract][Full Text] [Related]
5. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging.
Van Skike CE; Lin AL; Roberts Burbank R; Halloran JJ; Hernandez SF; Cuvillier J; Soto VY; Hussong SA; Jahrling JB; Javors MA; Hart MJ; Fischer KE; Austad SN; Galvan V
Aging Cell; 2020 Jan; 19(1):e13057. PubMed ID: 31693798
[TBL] [Abstract][Full Text] [Related]
6. mTOR drives cerebral blood flow and memory deficits in LDLR
Jahrling JB; Lin AL; DeRosa N; Hussong SA; Van Skike CE; Girotti M; Javors M; Zhao Q; Maslin LA; Asmis R; Galvan V
J Cereb Blood Flow Metab; 2018 Jan; 38(1):58-74. PubMed ID: 28511572
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the effect of rapamycin treatment in Alzheimer's disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol.
Svensson JE; Bolin M; Thor D; Williams PA; Brautaset R; Carlsson M; Sörensson P; Marlevi D; Spin-Neto R; Probst M; Hagman G; Morén AF; Kivipelto M; Plavén-Sigray P
BMC Neurol; 2024 Apr; 24(1):111. PubMed ID: 38575854
[TBL] [Abstract][Full Text] [Related]
8. Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the
Shi Q; Chang C; Saliba A; Bhat MA
J Neurosci; 2022 Jul; 42(27):5294-5313. PubMed ID: 35672148
[TBL] [Abstract][Full Text] [Related]
9. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story.
Richardson A; Galvan V; Lin AL; Oddo S
Exp Gerontol; 2015 Aug; 68():51-8. PubMed ID: 25481271
[TBL] [Abstract][Full Text] [Related]
10. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease.
Lin AL; Zheng W; Halloran JJ; Burbank RR; Hussong SA; Hart MJ; Javors M; Shih YY; Muir E; Solano Fonseca R; Strong R; Richardson AG; Lechleiter JD; Fox PT; Galvan V
J Cereb Blood Flow Metab; 2013 Sep; 33(9):1412-21. PubMed ID: 23801246
[TBL] [Abstract][Full Text] [Related]
11. Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease.
Uddin MS; Rahman MA; Kabir MT; Behl T; Mathew B; Perveen A; Barreto GE; Bin-Jumah MN; Abdel-Daim MM; Ashraf GM
IUBMB Life; 2020 Sep; 72(9):1843-1855. PubMed ID: 32472959
[TBL] [Abstract][Full Text] [Related]
12. Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model.
Chen J; Long Z; Li Y; Luo M; Luo S; He G
Int J Mol Med; 2019 Jul; 44(1):313-323. PubMed ID: 31115485
[TBL] [Abstract][Full Text] [Related]
13. Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway.
Wang X; Jia J
Biomed Pharmacother; 2023 May; 161():114473. PubMed ID: 36889111
[TBL] [Abstract][Full Text] [Related]
14. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.
Caccamo A; De Pinto V; Messina A; Branca C; Oddo S
J Neurosci; 2014 Jun; 34(23):7988-98. PubMed ID: 24899720
[TBL] [Abstract][Full Text] [Related]
15. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease.
Lin AL; Parikh I; Yanckello LM; White RS; Hartz AMS; Taylor CE; McCulloch SD; Thalman SW; Xia M; McCarty K; Ubele M; Head E; Hyder F; Sanganahalli BG
Neurobiol Dis; 2020 Jun; 139():104834. PubMed ID: 32173556
[TBL] [Abstract][Full Text] [Related]
16. [Effect of moxibustion on autophagy in mice with Alzheimer's disease based on mTOR/p70S6K signaling pathway].
Wu YY; Song XG; Zhu CF; Cai SC; Ge X; Wang L; Jia YM
Zhongguo Zhen Jiu; 2022 Sep; 42(9):1011-6. PubMed ID: 36075597
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease.
Lin AL; Jahrling JB; Zhang W; DeRosa N; Bakshi V; Romero P; Galvan V; Richardson A
J Cereb Blood Flow Metab; 2017 Jan; 37(1):217-226. PubMed ID: 26721390
[TBL] [Abstract][Full Text] [Related]
18. [Effect of mammalian target of rapamycin on cognitive dysfunction of Alzheimer's Disease via regulating Homer3].
Huang YQ; Liu XG; Zhang L; Yu Y; Xue J; Sun JL
Zhonghua Yi Xue Za Zhi; 2020 May; 100(17):1336-1340. PubMed ID: 32375443
[No Abstract] [Full Text] [Related]
19. Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease.
Pierce A; Podlutskaya N; Halloran JJ; Hussong SA; Lin PY; Burbank R; Hart MJ; Galvan V
J Neurochem; 2013 Mar; 124(6):880-93. PubMed ID: 23121022
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain.
Morawe MP; Liao F; Amberg W; van Bergeijk J; Chang R; Gulino M; Hamilton C; Hoft C; Lumpkin C; Mastis B; McGlame E; Nuber J; Plaas C; Ravikumar B; Roy K; Schanzenbächer M; Tierno J; Lakics V; Dellovade T; Townsend M
Eur J Pharmacol; 2022 Nov; 934():175301. PubMed ID: 36191631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
